Largest Ever flutiform® Study Confirms Effectiveness and Tolerability in Real-world Clinical Practice: Findings from AffIRM Study to be Presented at ERS 2017

New real-world data to be presented at the European Respiratory Society (ERS) annual congress in Milan, Italy, will show that the proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI (pressurised metered dose inhaler) compared with baseline.[1] flutiform (fluticasone propionate/formoterol) is indicated for use as a maintenance treatment for asthma patients aged 12 years and older where ICS/LABA therapy is appropriate....
. .
Veröffentlicht von: APA-OTS - Wirtschaft - Monday, 11 September
Share |